Jun 2026 (Q2 FY26) — Aug 4, 2026
Rigel Q2 FY26 — Vepinu In-License and Strong Commercial Performance Drive Growth
Read the full callRigel (RIGL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Rigel earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 78.7 | −22.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 29.9 | −30.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 17.3 | −71.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$47.25 +0.92% · +$0.43
Performance +72.6% 1Y
1Y: $27.38 on 14 Oct 2025 → $47.25. High $50.96 (26 Nov 2025), low $25.44 (18 Mar 2026).
- Previous close
- $46.82
- 52-week range
- $25.44 – $50.96
- One year
- +68.09%
Overview
- Symbol
- RIGL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Rigel earnings calls (RIGL)
Financials
What the filings say
Net profit, year on year: −71% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 55 | 58 | 53 | 102 | 69 | 70 | 59 | 79 |
| Expenses | 41 | 41 | 41 | 41 | 41 | 47 | 47 | 55 |
| Operating profit | 14 | 17 | 13 | 61 | 28 | 23 | 12 | 24 |
| Operating margin | 25.4% | 28.9% | 23.9% | 60.1% | 40.9% | 33.2% | 20.2% | 29.9% |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Profit before tax | 12 | 15 | 12 | 60 | 28 | 23 | 12 | 24 |
| Tax rate | 0.0% | 5.8% | 0.6% | 0.6% | −1.0% | −1080.2% | 25.8% | 26.7% |
| Net profit | 12 | 14 | 11 | 60 | 28 | 268 | 9 | 17 |
| EPS ($ per share) | 0.71 | — | 0.64 | 3.33 | 1.55 | — | 0.47 | 0.93 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,209 | -1,276 | -1,306 | -1,324 | -1,382 | -1,408 | -1,390 | -1,023 |
| Total liabilities | 29 | 94 | 76 | 137 | 148 | 146 | 161 | 122 |
| Fixed assets | 1 | 2 | 3 | 2 | 1 | 0 | 0 | 0 |
| Investments | 52 | 76 | 27 | 106 | 34 | 24 | 21 | 114 |
| Total assets | 139 | 148 | 110 | 167 | 134 | 117 | 164 | 514 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -59 | -42 | -52 | 6 | -74 | -6 | 31 | 76 |
| Cash from investing | 25 | -24 | 47 | -80 | 73 | -4 | 4 | -92 |
| Cash from financing | 72 | 11 | 13 | 63 | 7 | 18 | -12 | 1 |
| Capital expenditure | -1 | -1 | -1 | -1 | -0 | — | — | — |
| Free cash flow | -60 | -43 | -53 | 5 | -74 | — | — | — |
Insider filings
48 filings between Dec 22, 2025 and Sep 2, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$305.9K
3 sales by 2 insiders
67% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 13
- Award — granted as compensation
- 12
- Option exercise — converted options into shares
- 20
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Ali-Jackson Kamil | — | $160.4K | Jun 22, 2026 |
| MOOS WALTER H | — | $145.4K | Feb 20, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option exercise | 2,000 | $48.4K |
| Sep 2, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option exercise | 1,286 | $31.1K |
| Sep 2, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option exercise | 694 | $8.8K |
| Sep 2, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option exercise | 620 | $11.6K |
| Sep 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Tax withheld | 928 | $44.1K |
| Sep 1, 2026 | Santos David A EVP, Chief Commercial Officer | Tax withheld | 874 | $41.5K |
| Sep 1, 2026 | RODRIGUEZ RAUL R CEO, President | Tax withheld | 2,424 | $115.1K |
| Sep 1, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Tax withheld | 877 | $41.7K |
| Jul 8, 2026 | HANNAH ALISON L. EVP, Chief Medical Officer | Award | 24,400 | $0 |
| Jun 22, 2026 | Ali-Jackson Kamil Director | Sale 10b5-1 plan | 2,500 | $87.5K |
| Jun 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Tax withheld | 928 | $27.7K |
| Jun 1, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Tax withheld | 877 | $26.2K |
| Jun 1, 2026 | RODRIGUEZ RAUL R CEO, President | Tax withheld | 2,424 | $72.4K |
| Jun 1, 2026 | Rojkjaer Lisa EVP, Chief Medical Officer | Tax withheld | 850 | $25.4K |
| Jun 1, 2026 | Santos David A EVP, Chief Commercial Officer | Tax withheld | 874 | $26.1K |
| Jun 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option exercise | 1,200 | $22.4K |
| Jun 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option exercise | 2,181 | $27.7K |
| May 26, 2026 | Ali-Jackson Kamil Director | Sale 10b5-1 plan | 2,500 | $72.9K |
| May 15, 2026 | MOOS WALTER H Director | Award | 5,750 | $0 |
| May 15, 2026 | Wasman Jane Director | Award | 5,750 | $0 |
| May 15, 2026 | Ali-Jackson Kamil Director | Award | 5,750 | $0 |
| May 15, 2026 | Frohlich Mark W Director | Award | 5,750 | $0 |
| May 15, 2026 | HANNAH ALISON L. Director | Award | 5,750 | $0 |
| May 15, 2026 | MILLER MICHAEL PATRICK Director | Award | 5,750 | $0 |
| May 15, 2026 | LAPOINTE ANTHONY GREGG Director | Award | 5,750 | $0 |
| Feb 20, 2026 | MOOS WALTER H Director | Sale | 4,000 | $145.4K |
| Feb 20, 2026 | MOOS WALTER H Director | Option exercise | 4,000 | $96.0K |
| Feb 17, 2026 | Schorno Dean L EVP & Chief Financial Officer | Award | 20,636 | $0 |
| Feb 17, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Award | 19,497 | $0 |
| Feb 17, 2026 | RODRIGUEZ RAUL R CEO, President | Award | 53,915 | $0 |
| Feb 17, 2026 | Santos David A EVP, Chief Commercial Officer | Award | 19,430 | $0 |
| Feb 17, 2026 | Rojkjaer Lisa EVP, Chief Medical Officer | Award | 18,894 | $0 |
| Feb 10, 2026 | Schorno Dean L EVP & Chief Financial Officer | Tax withheld | 3,546 | $122.8K |
| Feb 10, 2026 | Santos David A EVP, Chief Commercial Officer | Tax withheld | 3,546 | $122.8K |
| Feb 10, 2026 | Rojkjaer Lisa EVP, Chief Medical Officer | Tax withheld | 3,758 | $130.1K |
| Feb 10, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Tax withheld | 3,546 | $122.8K |
| Feb 10, 2026 | RODRIGUEZ RAUL R CEO, President | Tax withheld | 7,607 | $263.4K |
| Feb 2, 2026 | Schorno Dean L EVP & Chief Financial Officer | Tax withheld | 5,488 | $197.6K |
| Feb 2, 2026 | RODRIGUEZ RAUL R CEO, President | Tax withheld | 14,110 | $508.1K |
| Feb 2, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Tax withheld | 3,968 | $142.9K |
| Feb 2, 2026 | Santos David A EVP, Chief Commercial Officer | Tax withheld | 5,718 | $205.9K |
| Jan 26, 2026 | RODRIGUEZ RAUL R CEO, President | Tax withheld | 35,424 | $1.31M |
| Jan 26, 2026 | RODRIGUEZ RAUL R CEO, President | Option exercise | 40,000 | $1.10M |
| Jan 26, 2026 | RODRIGUEZ RAUL R CEO, President | Tax withheld | 35,211 | $1.30M |
| Jan 26, 2026 | RODRIGUEZ RAUL R CEO, President | Option exercise | 40,000 | $1.10M |
| Dec 22, 2025 | Schorno Dean L EVP & Chief Financial Officer | Option exercise | 2,846 | $68.9K |
| Dec 22, 2025 | Schorno Dean L EVP & Chief Financial Officer | Option exercise | 1,987 | $39.7K |
| Dec 22, 2025 | Schorno Dean L EVP & Chief Financial Officer | Option exercise | 1,667 | $31.2K |
| May 23, 2025 | HANNAH ALISON L. Director | Award | 2,500 | $0 |
| May 23, 2025 | LAPOINTE ANTHONY GREGG Director | Award | 2,500 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for RIGEL PHARMACEUTICALS INC
Free account. Everything above stays public.
Write why you follow RIGEL PHARMACEUTICALS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading